Business Wire

CO-EXOLAUNCH

10.7.2024 08:02:26 CEST | Business Wire | Press release

Share
Exolaunch Successfully Deploys Satellites on Historic Ariane 6 Inaugural Launch, Enhancing European Access to Space

Exolaunch, the global leader in launch mission management, integration, and satellite deployment services, proudly announced the successful deployment of four satellites aboard Arianespace’s Ariane 6 maiden flight. The liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Representing customers ESA, NASA, and Spacemanic, this mission highlights Exolaunch’s crucial role in broadening access to space and supporting new launch vehicle providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709995719/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The historic Ariane 6 liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Photo credits: ESA, Arianespace, CNES.

This historic launch featured ESA’s ISTSat-1 and 3Cat-4, NASA’s CURIE, and Spacemanic’s GRBBeta satellites. The successful deployment of these satellites underscores Exolaunch’s commitment to facilitating groundbreaking scientific research and technological advancements through reliable and innovative satellite deployment solutions.

ESA’s ISTSat-1, developed by students at the Instituto Superior Técnico in Lisbon, aims to demonstrate ADS-B technology, validating detection capabilities and assessing antenna and receiver performance for receiving messages from commercial aircraft. 3Cat-4, a CubeSat from Universitat Politécnica de Catalunya, features a flexible microwave payload technology demonstrator with scientific objectives related to GNSS for Earth observation and AIS receiver validation.

NASA’s CURIE mission comprises two near-identical 3U CubeSats designed to explore low-frequency radio interferometry in space. These CubeSats will study solar radio bursts by maintaining a 1-3 km separation post-deployment, contributing to the understanding of heliospheric space weather and serving as a proof of concept for future space-based interferometry observatories.

Spacemanic’s GRBBeta, a 2U CubeSat, acts as a tech demonstration for the future CAMELOT constellation, aiming to detect and localize gamma-ray bursts from space. Managed by Spacemanic and led by the Technical University of Košice, this mission tests new subsystems, including an advanced GNSS positioning module and a radio modem for instant telemetry.

The successful launch of Ariane 6 represents a significant milestone for the European space industry, heralding a new era of enhanced access to space for European entities. Ariane 6 is designed to offer flexibility and cost-efficiency, making it an attractive option for various space missions. Through supporting this historic launch, Exolaunch reinforces its dedication to fostering growth and innovation in Europe’s space sector.

"Exolaunch is honored to have been part of the Ariane 6 maiden flight, working alongside Arianespace, ESA, and CNES to provide our customers with dependable access to space,” remarked Jeanne Allarie, chief commercial officer at Exolaunch. “We also extend congratulations to ESA, NASA, and Spacemanic on their successful satellite deployments. We are proud to support these innovative missions and look forward to the scientific and technological advancements they will each bring. This launch is not only a testament to the technical prowess and collaborative spirit of the European space community, but also a stepping stone towards a more robust, competitive European presence in the global space industry. We look forward to the opportunity to support future Ariane 6 launches and ensure that Europe remains at the forefront of space exploration.”

About Exolaunch

Exolaunch (Germany, USA) is a global leader in launch mission integration and deployment technologies. With a decade of flight heritage and nearly 400 satellites launched across 29 missions to date, Exolaunch leverages industry insight to tailor turnkey solutions that meet customer needs and respond to market trends. Exolaunch fulfills launch contracts for industry leaders, the world's most innovative start-ups, research institutions, government organizations, and international space agencies. The company develops and manufactures its own flight-proven and industry-leading small satellite separation systems, with the fastest-growing heritage on the market. Exolaunch promotes safe, sustainable, and responsible use of space and is committed to making space accessible for all.

For more information, please visit www.exolaunch.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709995719/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye